What type of study is this?

This is a In Vitro Study study.

December 8, 2025Blood

Disrupting a new NFkB-IL-6-JAK2-STAT cascade with novel NFkB inhibitors reduces primary myelofibrosis growth

View Full Paper

Ask AI

Bookmark

Authors

Research reveals IL-6 and NFkB inhibition reduces primary myelofibrosis growth, suggesting new treatment approaches.

Suppression of IL-6 and NFkB reduces growth of primary myelofibrosis tumors and improves outcomes.
Tumor volume significantly decreased from 734 mm3 to 98 mm3 after Ixazomib treatment, indicating strong efficacy.
Transcriptional analysis highlighted unique NFkB pathway activation in primary myelofibrosis compared to other types.
New therapeutic strategies involving Ixazomib and emetine may offer promising alternatives to standard JAK inhibitors.

Gangat et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Research reveals IL-6 and NFkB inhibition reduces primary myelofibrosis growth, suggesting new treatment approaches.

Suppression of IL-6 and NFkB reduces growth of primary myelofibrosis tumors and improves outcomes.
Tumor volume significantly decreased from 734 mm3 to 98 mm3 after Ixazomib treatment, indicating strong efficacy.
Transcriptional analysis highlighted unique NFkB pathway activation in primary myelofibrosis compared to other types.
New therapeutic strategies involving Ixazomib and emetine may offer promising alternatives to standard JAK inhibitors.

Gangat et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark